Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research report released on Wednesday morning. The firm issued a sell rating on the biotechnology company’s stock.

CLLS has been the subject of several other research reports. Oppenheimer cut their price objective on Cellectis from $11.00 to $10.00 and set an outperform rating for the company in a report on Wednesday, June 12th. JMP Securities reissued a market outperform rating and issued a $6.00 price target on shares of Cellectis in a report on Friday, May 31st.

Cellectis Stock Down 2.7 %

Cellectis stock opened at $2.26 on Wednesday. Cellectis has a 52 week low of $0.96 and a 52 week high of $3.77. The stock has a market cap of $125.45 million, a price-to-earnings ratio of -1.75 and a beta of 3.09. The company’s 50-day moving average price is $2.21 and its two-hundred day moving average price is $2.42. The company has a current ratio of 1.92, a quick ratio of 1.92 and a debt-to-equity ratio of 0.39.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. The business had revenue of $9.50 million for the quarter, compared to analyst estimates of $6.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. On average, analysts expect that Cellectis will post -0.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellectis

A number of institutional investors and hedge funds have recently modified their holdings of CLLS. Long Focus Capital Management LLC raised its position in shares of Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares during the period. XTX Topco Ltd purchased a new position in Cellectis in the 2nd quarter worth about $29,000. Principal Financial Group Inc. raised its holdings in Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after buying an additional 12,467 shares during the period. Finally, Baillie Gifford & Co. lifted its stake in Cellectis by 1.3% during the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after buying an additional 10,605 shares in the last quarter. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.